Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), today announced the acquisition of the ACTIA (Autologous Cell Therapy Industrial Automation) Platform IP, developed by Geoff Hodge whilst CEO of SOTIO Biotech US. The ACTIA Platform complements Cellular Origins’ existing approach and will accelerate and expand R&D efforts to further develop the Company’s robotic solution for automated cell therapy manufacturing, Constellation™.
NIH funds study on environmental impact on male fertility
A grant from the National Institutes of Health will support ongoing research at Wayne State University investigating the consequences environmental factors may have on fertility
September 18, 2024